Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
This article was originally published in PharmAsia News
Executive Summary
Japan's largest drug maker, Takeda Pharmaceuticals Co. Ltd., may be close to buying private-equity owned Nycomed AS, based in Switzerland, for about $12 billion
You may also be interested in...
Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention
TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business
Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention
TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity